http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012112524-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 |
| filingDate | 2010-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012112524-A |
| titleOfInvention | USE OF A POPULATION OF IMMUNO REGULATORY NK CELLS FOR MONITORING EFFECTIVENESS OF ANTIBODIES AGAINST IL-2R IN PATIENTS WITH MULTIPLE SCLEROSIS |
| abstract | 1. A method for monitoring the effectiveness of an anti-IL-2R antibody in a patient diagnosed with multiple sclerosis, comprising determining the level of CD56NK cells in blood samples obtained from a patient diagnosed with multiple sclerosis before and after administration of at least the first dose of an antibody against IL-2R, wherein an increase in CD56NK cell levels in a patient following administration of the indicated dose of anti-IL-2R antibody indicates that the anti-IL-2R antibody is effective in alleviating at least one symptom of multiple sclerosis in the patient being treated. The method of claim 1, wherein the blood sample is collected within 14 days of the first dose of anti-IL-2R antibody. The method of claim 1, wherein the blood sample is collected after administration of the second dose, third dose, fourth dose, fifth dose, or sixth dose of anti-IL-2R antibody. The method of claim 1, wherein the blood sample is collected after administration of the second dose, third dose, fourth dose, fifth dose, and sixth dose of anti-IL-2R antibody. A method for monitoring the response to an anti-IL-2R antibody in a patient diagnosed with multiple sclerosis, comprising comparing the level of CD56NK cells in a patient diagnosed with multiple sclerosis between 5 and 14 days after the first dose of anti-IL-2R antibody with a reference number of CD56NK cells, while increasing The level of CD56NK cells after administration of the first dose of anti-IL-2R antibody compared to the reference number of CD56NK cells indicates the effectiveness of treatment with anti-IL-2R antibody to alleviate at least one symptom of multiple sclerosis in the patient being treated. The method according to claim 5, wherein the reference number is from 4.4±3.8 to 8.8±8.7 CD56NK cells |
| priorityDate | 2009-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.